Ocular Therapeutix (OCUL) Gets a Buy From Piper Sandler
Piper Sandler Sticks to Their Buy Rating for Ocular Therapeutix (OCUL)
Ocular Therapeutix Jumps as TD Cowen Upgrades to Buy and Hikes PT
Ocular Therapeutix Analyst Ratings
Ocular Therapeutix Analyst Ratings
Piper Sandler Starts Ocular Therapeutix With Overweight Rating, $15 Price Target
Analysts Have Conflicting Sentiments on These Healthcare Companies: Immunocore Holdings (IMCR), Warby Parker (WRBY) and Ocular Therapeutix (OCUL)
HC Wainwright & Co. Maintains Buy on Ocular Therapeutix, Lowers Price Target to $14
JMP Securities Maintains Market Outperform on Ocular Therapeutix, Lowers Price Target to $22
Ocular Therapeutix Analyst Ratings
TD Cowen Maintains Hold on Ocular Therapeutix, Lowers Price Target to $7
Maintaining Buy Rating on Ocular Therapeutix: Financial Growth and Advancements in Clinical Trials Signal Strong Prospects
Analysts Have Conflicting Sentiments on These Healthcare Companies: Ocular Therapeutix (OCUL) and ModivCare (MODV)
Optimistic Buy Rating for Ocular Therapeutix Amid Early-Stage NPDR Study and Wet AMD Potential
Analysts Offer Insights on Healthcare Companies: Alkermes (ALKS) and Ocular Therapeutix (OCUL)
Ocular Therapeutix Analyst Ratings
Analysts Offer Insights on Healthcare Companies: Walgreens Boots Alliance (WBA), Ocular Therapeutix (OCUL) and Elevance Health (ELV)
Ocular Therapeutix Analyst Ratings
Analysts Are Bullish on Top Healthcare Stocks: OptimizeRx (OPRX), Ocular Therapeutix (OCUL)
Ocular Therapeutix (OCUL) Gets a Buy From Piper Sandler